List of Excipients in Branded Drug IRBESARTAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Winthrop US a business of sanofi-aventis US LLC	IRBESARTAN	irbesartan	0955-1040	CARNAUBA WAX
Winthrop US a business of sanofi-aventis US LLC	IRBESARTAN	irbesartan	0955-1040	CELLULOSE, MICROCRYSTALLINE
Winthrop US a business of sanofi-aventis US LLC	IRBESARTAN	irbesartan	0955-1040	CROSCARMELLOSE SODIUM
Winthrop US a business of sanofi-aventis US LLC	IRBESARTAN	irbesartan	0955-1040	HYPROMELLOSE
Winthrop US a business of sanofi-aventis US LLC	IRBESARTAN	irbesartan	0955-1040	LACTOSE MONOHYDRATE

Generic Drugs Containing IRBESARTAN

Company	Ingredient	NDC	Excipient
Unichem Pharmaceuticals (USA) Inc	irbesartan	29300-212	CROSCARMELLOSE SODIUM
Unichem Pharmaceuticals (USA) Inc	irbesartan	29300-212	MAGNESIUM STEARATE
Unichem Pharmaceuticals (USA) Inc	irbesartan	29300-212	MANNITOL
Unichem Pharmaceuticals (USA) Inc	irbesartan	29300-212	POLOXAMER 188
Unichem Pharmaceuticals (USA) Inc	irbesartan	29300-212	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in IRBESARTAN?

# Of NDCs	Excipient
16	CALCIUM STEARATE
25	CARBOXYMETHYLCELLULOSE CALCIUM
39	CELLULOSE, MICROCRYSTALLINE
32	CROSCARMELLOSE SODIUM
2	CROSPOVIDONE

Excipient Strategy and Commercial Opportunities for Irbesartan

Last updated: February 25, 2026

Irbesartan, an angiotensin II receptor blocker (ARB), is used primarily for hypertension and diabetic nephropathy. Its formulation heavily depends on excipients, impacting stability, bioavailability, patient compliance, and manufacturing efficiency. Strategic excipient selection and innovative formulation approaches can open new commercial pathways.

What Are Relevant Excipient Strategies for Irbesartan?

1. Enhancing Bioavailability and Stability

Irbesartan has low water solubility, classified as BCS Class II. To improve oral absorption, formulations use excipients like:

• Surfactants: Sodium lauryl sulfate or poloxamers to increase dissolution.
• Cyclodextrins: Encapsulate irbesartan to improve solubility.
• Lipid-based excipients: Self-emulsifying drug delivery systems (SEDDS) with surfactants and oils to enhance absorption.

2. Formulation Optimization

Strategies include:

• Solid dispersions: Use of polymers such as povidone or hydroxypropyl methylcellulose (HPMC) to maintain stability and improve dissolution.
• Nanotechnology: Nanocrystals or nanoparticles to boost surface area and absorption.
• Controlled-release systems: Matrix polymers like ethylcellulose for sustained release, reducing dosing frequency.

3. Excipient Compatibility and Regulatory Environment

Selection relies on:

• Compatibility with active pharmaceutical ingredient (API)
• Regulatory approval status
• Low toxicity profile
• Manufacturing feasibility

Polymers like HPMC and Eudragit are well-established, reducing regulatory hurdles.

Commercial Opportunities Based on Excipient Strategies

1. Abbreviating Development Using Established Excipient Systems

Leveraging known excipients accelerates regulatory approval. Formulations utilizing standard polymers or surfactants enable faster market entry, especially in emerging markets.

2. Development of Patent-Protected Formulations

Novel delivery systems, such as SEDDS or nanocrystals, can be patented, extending product lifecycle. These protect against generic competition and generate licensing revenue.

3. Expanding Indications

Enhanced formulations that improve bioavailability or patient compliance can support new indications, like combination therapies or fixed-dose combinations with other antihypertensives.

4. Generic and Branded Opportunities

Generic manufacturers can adopt advanced excipient strategies to differentiate products, offering improved absorption or reduced side effects for premium pricing.

5. Personalized Medicine and Patient-Specific Formulations

Nanotechnology and targeted delivery open pathways for formulations tailored to specific populations, such as pediatric or renal-impaired patients.

Market Data and Trends

Aspect	Data Point	Source
Global antihypertensive market size	USD 33 billion in 2021	[1]
Irbesartan market share	Estimated 10-15% of ARB segment	[2]
Focus on solubility enhancement	35% of new ARB formulations incorporate excipient modifications	[3]
Use of self-emulsifying formulations	Seen in 20% of recent ARB products launched in Asia	[4]
Patents on irbesartan formulations	Expiry dates from 2025 onward	[5]

Key Considerations

• Formulation complexity can increase costs but adds value through improved efficacy.
• Regulatory pathways favor known excipients, but novel systems require comprehensive safety data.
• Patent protection depends on novelty of excipient combination or delivery method.

Key Takeaways

• Excipient strategies for irbesartan focus on improving solubility, bioavailability, and patient compliance.
• Lipid-based and nanotechnology approaches present significant commercial opportunities.
• Leveraging existing excipients accelerates regulatory approval; novel systems can extend patent life.
• Enhanced formulations allow for indication expansion and differentiation in competitive markets.
• Dynamic market growth supports innovation in excipient use, particularly in emerging markets and personalized therapies.

FAQs

1. How can excipient choice impact irbesartan’s bioavailability?
Excipients like surfactants and cyclodextrins enhance solubility, which is critical for irbesartan’s absorption due to its low water solubility.

2. What excipients are commonly used in irbesartan formulations?
Hydroxypropyl methylcellulose, Eudragit polymers, sodium lauryl sulfate, and cyclodextrins.

3. What are the regulatory challenges for novel excipient systems?
Safety and toxicity data are necessary, especially for new excipients or delivery systems like nanocrystals.

4. Can excipient strategies help extend irbesartan’s patent life?
Yes, patenting new delivery methods or formulations using novel excipients can prolong exclusivity.

5. Are there emerging trends in excipient use for antihypertensive drugs?
Yes, lipid-based systems, nanotechnology, and controlled-release formulations increase drug efficacy and patient adherence.

---

References

[1] Markets and Markets. (2022). Hypertension Drugs Market Analysis.
[2] IQVIA. (2021). Global ARB Market Share Report.
[3] Drug Development Journal. (2020). Advances in BCS Class II Drug Formulations.
[4] Asian Pharmaceutical Innovation. (2021). Trends in ARB Formulation Development.
[5] PatentScope. (2022). Irbesartan Formulation Patents.